CEntralized Pan-Russian survey of tHE Undertreatment of hypercholeSterolemia II
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 May 2016 by AstraZeneca
No locations available
Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.